We develop drug candidates to advance into the clinic with pharmaceutical partners

New solutions and new therapies need new avenues to reach them. The age of cells producing biological compounds has achieved a lot for human medicine, but its means are coming to an end. A step change in technology is required to unleash the potential of molecules we didn’t dream we would discover – or be able to create if we did.

ELEVA is opening this realm of unprecedented therapies with the help of an inconspicuous but incredibly efficient tool: Bryophyta, more commonly known as moss. This ancient organism holds the key to the therapies of the future. Moss plants are not only able to produce the most complex and demanding proteins; with their unique characteristics, they virtually invite easy, stable engineering and reliable output.

Fact bites about eleva
Has 30 amazing staff
Located in Freiburg, in Germany’s South-West corner close to the Black Forest
Started out as Greenovation in 1999, where all the technology was developed into the trailblazing platform it is now
Can’t wait to see those new therapies happening!
Fact bites about eleva
Has 30 amazing staff
Located in Freiburg, in Germany’s South-West corner close to the Black Forest
Started out as Greenovation in 1999, where all the technology was developed into the trailblazing platform it is now
Can’t wait to see those new therapies happening!
Business model​

At Eleva ...

We develop clinical assets in partnership with pharmaceutical companies
… we develop complex proteins into tomorrow’s drugs in partnership with pharmaceutical companies
We unlock the potential of difficult compounds that have so far failed to get expressed

… we unlock the potential of difficult compounds that have so far failed to get expressed

We explore unusual opportunities in other promising fields

… we explore unusual opportunities in other promising fields

We have successfully developed enzymes and other proteins into clinical stages and continue to scout for promising compounds. This results in a plethora of opportunities. Whilst our technology platform remains the property of Eleva, new individual assets will be developed in cooperation with pharmaceutical partners. Each of such partnerships will be taken into a newly formed subsidiary. This allows the partners to focus on the respective indication.


Making unprecedented and much-needed therapies happen

Eleva’s management is driven by making unprecedented and much-needed therapies happen. With our moss-based platform, we are going to translate the features of this ancient plant into the therapies of tomorrow.

Dr. Andreas Schaaf, Managing Director | CSO
Andreas Schaaf Managing Director | CSO
Andreas holds a PhD in plant biotechnology. Before joining Greenovation as research scientist in 2009, he held positions at the University of Muenster and Freiburg, Germany. At Greenovation, Andreas was responsible for advancing BryoTechnology to a fully viable biopharmaceutical platform. Andreas has been Chief Scientific Officer since 2015 and was appointed Managing Director at the end of 2019.
Ralf Smit, Managing Director | CBO
Ralf Smit Managing Director | CBO
Ralf Smit holds a PhD in microbiology from the University of Münster, Germany. He has held various positions in clinical development, business development and commercialisation in the pharmaceutical industry, advancing neurosciences and rare diseases as a Senior Director at Roche, and serving as CEO of BioStrat. A long-term advisor to Eleva, Dr. Smit has been heading its Clinical and Business Development since January 2021.
Jana Gross, Director Business Development
Jana Gross Director Business Development
Jana holds a Master’s Degree in biology from Ruprecht-Karls-University, Heidelberg, Germany. She worked in Intellectual Property and Technology Transfer before moving to an international pharmaceutical company, where she managed Global Licensing & Business Alliances. Jana has been the Manager of Business Development at Eleva since October 2019.
Danielle Püschel, Director Finance and Administration
Danielle Püschel Chief Financial Officer | CFO
Danielle joined Greenovation in 2009 as Chief Financial Officer, after 25 years’ experience as a tax advisor for several small and medium-sized companies. At Eleva, Danielle is responsible for Finance, Administration and Human Resources.
Karin Heidenreich, Director Medical Alliance
Karin Heidenreich Director Medical Alliance
Karin graduated in chemistry at the University of Leipzig, Germany. Before joining Eleva in 2018, she held various positions in academia and in global pharmaceutical companies, covering sales and medical alliances. At Eleva, she co-ordinates all contacts with medical and patient organisations as well as key medical advisers.
Andreas Busch, Director Operations and Regulatory Affairs
Andreas Busch Chief Operations Officer | COO
Andreas earned his PhD at the University of Münster, Germany, after graduating in biology from Friedrich-Schiller-Universität Jena, Germany. He worked as a post-doc in Münster and at the University of Copenhagen, Denmark. Andreas joined Eleva in 2013 and is now responsible for Operations and Regulatory Affairs.
Advisory Board

Tapping into world-class expertise with our advisors

Eleva is fortunate to be able to tap into world-class expertise. We deeply value the guidance given by the following specialists:

Günter Steffen

Chair of Board

Dr. Gerhard Ries

Co-Chair of Board

Prof. Dr. Joachim Cyran

Member of the Board

Dr. Martin Griot

Member of the Board

Prof. Dr. Ralf Reski

Member of the Board

Dr. Wieland Wolf

Member of the Board

Company values

Eleva’s company values ensure that relationships with partners and employees are guided by reliability and respect. Quality is the prime goal throughout the company. Our guidelines are continuously reviewed. 

Our success is based on our highly motivated staff. We have zero tolerance for discrimination of employees on the grounds of their sexual orientation, sex, ethnicity, religion, family status, age, or disability. We provide a safe workplace as well as continuous training and respect of privacy for every staff member.


Working towards tomorrow’s therapies for today’s unmet needs

Unfortunately, we have no vacancies at this point in time.

Prof. Dr. Gunther Neuhaus

Obituary of our co-founder: Eleva says goodbye to Gunther Neuhaus

In silent mourning we bid farewell to one of our company founders and shareholders Prof. Dr. Gunther Neuhaus. He passed away on July 10, 2021 at the age of 67.      

Gunther Neuhaus was born in Linz in 1953. He studied biology at the University of Salzburg and graduated with a doctorate in 1980. This was followed by a habilitation at the Swiss Federal Institute of Technology in Zurich. In 1995, Gunther Neuhaus became Professor of Cell Biology at the University of Freiburg. He headed the Centre for Applied Biosciences and was elected prorector for research.

Gunther Neuhaus was well known as an outstanding scientist. He was also instrumental in developing the moss bioreactor platform by co-founding the Greenovation Biotech GmbH in 1999. Thanks to his commitment and constant support, Eleva is on the way to develop therapeutic proteins for human diseases with the potential to improve the lives of underserved patients. We will miss and remember Gunther as a warm-hearted colleague, a friend and a founder. Our heartfelt condolences go out to his family.